Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | Fruquintinib + Tislelizumab |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Fruquintinib | HMPL-013 | VEGFR Inhibitor (Pan) 33 | Fruquintinib (HMPL-013) binds and inhibits VEGFR receptors, 1,2 and 3, resulting in reduced cell proliferation and tumor growth (PMID: 25482937, PMID: 31790382). | |
Tislelizumab | BGB-A317 | Immune Checkpoint Inhibitor 151 PD-L1/PD-1 antibody 98 | Tislelizumab (BGB-A317) is a human monoclonal antibody that targets PD-1 (PDCD1), thereby blocking the binding of PD-L1 (CD274) and potentially resulting in activation of a T-cell immune response against tumor cells (PMID: 32769013, PMID: 32561638, PMID: 32540858). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04577963 | Phase Ib/II | Fruquintinib + Tislelizumab | A Study of Fruquintinib in Combination With Tislelizumab in Advanced Triple Negative Breast Cancer | Recruiting | USA | 0 |